Reports of the death of Cost-Effectiveness Analysis in the U.S. may have been exaggerated: The ongoing case of Mammography
Guidelines for the use of mammograms to screen for breast cancer have been the topic of one of the fiercest and longest-running debates in medicine. Back in the early 1990s, I participated in that debate as the leader of a guideline development team at the Henry Ford Health System. We developed one of the earliest








